PubMed 42738950

Effects of a Combined Vitamin D3 and Docosahexaenoic Acid Intervention on Cognitive Function and Blood Pyroptotic Biomarkers in Older Adults with Mild Cognitive Impairment: A 12-Month Randomized, Double-Blind, Placebo-Controlled Trial

Yuan J et al. · Nutrients · 2026 · PubMed · DOI 10.3390/nu18172777

Summary

Drafted from the abstract by an automated step and checked field by field against that same abstract by another automated pass, not by a person. It reports what the authors reported, in their terms. It is not medical advice and it is not about any product on this site.

Effects of a Combined Vitamin D3 and Docosahexaenoic Acid Intervention on Cognitive Function and Blood Pyroptotic Biomarkers in Older Adults with Mild Cognitive Impairment: A 12-Month Randomized, Double-Blind, Placebo-Controlled Trial

随机对照试验Machine-checked 2026年9月21日AI-assisted draft

Yuan J et al. Effects of a Combined Vitamin D3 and Docosahexaenoic Acid Intervention on Cognitive Function and Blood Pyroptotic Biomarkers in Older Adults with Mild Cognitive Impairment: A 12-Month Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients, 2026. PubMed 42738950 · DOI

Design
Randomized, double-blind, placebo-controlled trial with four parallel arms over 12 months. Linear mixed-effects models assessed cognitive and biomarker changes; structural equation modeling assessed mediation of biomarkers on cognitive improvement.
Population
360 older adults with mild cognitive impairment (MCI) were enrolled; 355 completed the trial.
Intervention
Participants received vitamin D3 alone, DHA alone, vitamin D3 plus DHA combined, or placebo.
Dose as studied
Vitamin D3 800 IU/day; DHA 1 g/day; combined arm received both at these doses.
Comparator
Placebo.
Duration
12 months, with assessments at baseline, 6 months, and 12 months.

Outcomes, as reported

  • Cognitive function (WAIS-RC: full-scale, performance, verbal IQ and subtests) All intervention groups showed significant improvements vs placebo (p<0.05); combined VD3+DHA showed superior improvements vs each single intervention in FIQ, PIQ, VIQ and several subtests.
  • Blood pyroptotic biomarkers (IL-1β, IL-18, NLRP3, GSDMD, cleaved caspase-1) All intervention groups showed significant reductions vs placebo (p<0.05); combined intervention reduced all five biomarkers significantly more than single interventions (p<0.05).
  • Mediation of cognitive improvement Path analysis showed longitudinal GSDMD reduction mediated improvement in full-scale IQ (FIQ).

Limitations stated by the authors · Not stated in the abstract.

Funding · Not stated in the abstract.